record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
contested
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundobservational · manual state transition · Homo sapiens
proof impact
packet context3 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
species
Homo sapiens
evidence spans
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
FDA approval materials, CMS coverage decisions, and sponsor discontinuation notices · curator_source · https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information
conditions
Provenance
source title
FDA approval materials, CMS coverage decisions, and sponsor discontinuation notices
authors
reviewer:will-blair-bot
Aducanumab approval did not establish a stable clinical translation pathway for anti-amyloid therapy because the program was discontinued after contested evidence and restricted uptake.
vs_18c998c2035325a6 · source:FDA approval materials, CMS coverage decisions, and sponsor discontinuation notices|section:curator_source · manual_curation
outgoing
vf_f738e7618b5339b8post-approval history extends the contested efficacy record
incoming
No incoming links.
events
vev_44f1a5f04c58fcf8finding.notedRegulatory source reg-fda-aducanumab changed tracked source fields: source locator changed from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aduhelm-aducanumab-avwa-information to https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information. Review whether this affects the linked finding scope, trial table, or decision brief; source metadata alone does not change the claim.
reviewer:will-blair-bot · 2026-05-06
vev_93f4fe25cdc8802efinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_d3ad8fcddb85049efinding.reviewedRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_1d0faeb172ca1b81finding.noteReview regulatory source record delta for reg-fda-aducanumab from run sir_4c5bbc2d54bb56be
applied · reviewer:will-blair-bot · 2026-05-06
vpr_3ac95fdf616023a7finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_e242b8fa10d4df8cfinding.reviewRegulatory history is factual, but its implication for the anti-amyloid class remains contested.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.